BOSTON, May 02, 2024, the global full-service clinical Contract Research Organization.
Novotech's Chief Medical Officer Dr. Judith Ng-Cashinstated: "We welcome Scott to the medical and scientific team. He is a proven strategic, innovative, and business focused life sciences executive with ~30 year of experience across the biopharma and CRO sectors. He brings valuable leadership to our world-class DDC team, a full-service global drug development and strategic regulatory team providing comprehensive "inception to approval" services."
The DDC partnerswith biotechs to optimize a fit-for purpose therapeutic development strategy that both advances the development program and creates value for the company. To do this, DDC leverages CMC/manufacturing, toxicology, clinical/medical and regulatory affairs experts with extensive industry experience covering all phases ?of drug development. It also offers a fully integrated regulatory affairs team with an experienced, speed orientated mindset to increase the probability of regulatory and commercial success.?
The DDC team has experience in a comprehensive range of indications for drugs, novel antibodies, recombinant protein therapeutics, small molecules, vaccines, cell therapy, devices, and combination products, throughout all phases of program development (Phases I - IV) and commercialization.
Scott Schliebner said he was extremely pleased to join the DDC team. "I bring a strategic and consultative approach to building and growing life sciences businesses, with a focus on developing relationships, partnerships, and collaborations that drive commercial success. I am also passionate about leveraging data and technology including RWE/RWD, technological innovation, and patient-focused paradigms to accelerate clinical drug development," he said.
Schliebner, who is US-based, holds a Master's Degree in Public Health in Biostatistics from the University of Utah School of Medicine and completed a Graduate Research Fellowship at The National Institutes of Health/NINDS.
https://www.linkedin.com/in/scott-schliebner-1087789/
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com